PURPOSE: A challenge in management of breast cancer is the development of brain metastases (BM). Because of improvements in systemic therapy with longer survival of patients with advanced cancer, BM can appear at a time when extra-BM disease is under control. Development of potential preventive strategies are considered, and new developments in systemic approaches to treatment of BM, (cytotoxic/targeted therapy), are explored. In primary breast cancer, ER/PR, HER2 are important biological markers for predicting prognosis and making effective treatment decisions. Known are changes in markers due to metastases, but clinical significance is still unclear. Aim of this retrospective study is to detect changes in immunohistochemical markers of primary and BM, to recognize concordance and impact on prognosis. METHODS: Twenty-one consecutive primary breast cancer patients who developed BM and got surgical resection of BM were enrolled in this study. Matched-pair analyses of primary and BM were done with evaluation by immunostaining (ER, PR, HER2). RESULTS: Loss of ER/PR receptor positivity was seen in BM compared to primary (ER: 47.6 %/9.0 %; PR: 42.9 %/0 %), respectively. High concordance exists for HER2 status in primary and BM (>80 %). HER2-positive breast cancer had a shorter median interval until appearance of metastases than HER2-negative patients (32.1/39 months; p = n.s.). CONCLUSION: With loss of receptor positivity (ER/PR) in BM treatment, decisions are very difficult. High concordance of HER2 status was seen in matched-pair analysis. Further studies had to investigate whether HER3/4 is a possible target for further therapy.
PURPOSE: A challenge in management of breast cancer is the development of brain metastases (BM). Because of improvements in systemic therapy with longer survival of patients with advanced cancer, BM can appear at a time when extra-BM disease is under control. Development of potential preventive strategies are considered, and new developments in systemic approaches to treatment of BM, (cytotoxic/targeted therapy), are explored. In primary breast cancer, ER/PR, HER2 are important biological markers for predicting prognosis and making effective treatment decisions. Known are changes in markers due to metastases, but clinical significance is still unclear. Aim of this retrospective study is to detect changes in immunohistochemical markers of primary and BM, to recognize concordance and impact on prognosis. METHODS: Twenty-one consecutive primary breast cancerpatients who developed BM and got surgical resection of BM were enrolled in this study. Matched-pair analyses of primary and BM were done with evaluation by immunostaining (ER, PR, HER2). RESULTS: Loss of ER/PR receptor positivity was seen in BM compared to primary (ER: 47.6 %/9.0 %; PR: 42.9 %/0 %), respectively. High concordance exists for HER2 status in primary and BM (>80 %). HER2-positive breast cancer had a shorter median interval until appearance of metastases than HER2-negative patients (32.1/39 months; p = n.s.). CONCLUSION: With loss of receptor positivity (ER/PR) in BM treatment, decisions are very difficult. High concordance of HER2 status was seen in matched-pair analysis. Further studies had to investigate whether HER3/4 is a possible target for further therapy.
Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart Journal: Lancet Date: 2007-01-06 Impact factor: 79.321
Authors: B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2006-04-07 Impact factor: 32.976
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Elyse E Lower; D Randolph Drosick; Robbin Blau; Lawrence Brennan; William Danneman; Douglas K Hawley Journal: Clin Breast Cancer Date: 2003-06 Impact factor: 3.225
Authors: Susanne Taucher; Margaretha Rudas; Robert M Mader; Michael Gnant; Peter Dubsky; Thomas Bachleitner; Sebastian Roka; Florian Fitzal; Daniela Kandioler; Emanuel Sporn; Josef Friedl; Martina Mittlböck; Raimund Jakesz Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: S Dawood; K Broglio; F J Esteva; W Yang; S-W Kau; R Islam; C Albarracin; T K Yu; M Green; G N Hortobagyi; A M Gonzalez-Angulo Journal: Ann Oncol Date: 2009-01-15 Impact factor: 32.976
Authors: C Bachmann; S Schmidt; A Staebler; T Fehm; F Fend; J Schittenhelm; D Wallwiener; E Grischke Journal: Med Oncol Date: 2014-11-30 Impact factor: 3.064
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Sherise D Ferguson; Siyuan Zheng; Joanne Xiu; Shouhao Zhou; Mustafa Khasraw; Priscilla K Brastianos; Santosh Kesari; Jethro Hu; Jeremy Rudnick; Michael E Salacz; David Piccioni; Suyun Huang; Michael A Davies; Isabella C Glitza; John V Heymach; Jianjun Zhang; Nuhad K Ibrahim; John F DeGroot; Joseph McCarty; Barbara J O'Brien; Raymond Sawaya; Roeland G W Verhaak; Sandeep K Reddy; Waldemar Priebe; Zoran Gatalica; David Spetzler; Amy B Heimberger Journal: Int J Cancer Date: 2018-10-09 Impact factor: 7.396
Authors: Athina Giannoudis; Kim Clarke; Rasheed Zakaria; Damir Varešlija; Mosavar Farahani; Lucille Rainbow; Angela Platt-Higgins; Stuart Ruthven; Katherine A Brougham; Philip S Rudland; Michael D Jenkinson; Leonie S Young; Francesco Falciani; Carlo Palmieri Journal: Sci Rep Date: 2019-12-06 Impact factor: 4.379